Emilia Górzyńska

Ms. Emilia Górzyńska

Institute of Nuclear Chemistry and Technology
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2020 in Nanomaterials
Verified
Journal Article
Open access
PDF file
ACAdrianna Cytryniak
Adrianna Cytryniak
ENEwa Nazaruk
Ewa Nazaruk
Renata BilewiczRenata Bilewicz
Renata Bilewicz
EGEmilia Górzyńska
Emilia Górzyńska
KŻKinga Żelechowska-Matysiak
Kinga Żelechowska-Matysiak
AMAgnieszka Majkowska-Pilip
Agnieszka Majkowska-Pilip
Lipid liquid-crystalline nanoparticles (cubosomes) were used for the first time as a dual-modality drug delivery system for internal radiotherapy combined with chemotherapy. Monoolein (GMO)-based cubosomes were prepared by loading the anticancer drug, doxorubicin and a commonly used radionuclide, low-energy beta (β−)-emitter, 177Lu. The radionuclide was complexed with a long chain derivative of DOTAGA (DOTAGA-OA). The DOTAGA headgroup of the chelator was exposed to the aqueous channels of the cubosomes, while, concerning OA, the hydrophobic tail was embedded in the nonpolar region of the lipid bilayer matrix, placing the radioactive dopant in a stable manner inside the cubosome. The cubosomes containing doxorubicin and the radionuclide complex increased the cytotoxicity measured by the viability of the treated HeLa cells compared with the effect of single-drug cubosomes containing either the DOX DOTAGA-OA or DOTAGA-OA-177Lu complex. Multifunctional lipidic nanoparticles encapsulating the chemotherapeutic agent together with appropriately complexed (β−) radionuclide are proposed as a potential strategy for effective local therapy of various cancers.

17 March 2026 in Bio-Algorithms and Med-Systems
Verified
Journal Article
Closed access
EGEmilia Górzyńska
Emilia Górzyńska
RWRafał Walczak
Rafał Walczak
MŁMonika Łyczko
Monika Łyczko
AMAgata Malinowska
Agata Malinowska
KLKrzysztof Lyczko
Krzysztof Lyczko
AMAgnieszka Majkowska-Pilip
Agnieszka Majkowska-Pilip
Introduction: This study aimed to develop a novel therapeutic strategy for treatment- -resistant cancers based on nano-brachytherapy, using gold nanoparticles as carriers for the Auger-electron–emitting radionuclides 197mHg and 197Hg. Methods: Five-nanometre PEGylated gold nanoparticles were functionalised with 197mHg/197Hg via surface amalgamation and evaluated in vitro in triple-negative breast cancer (MDA-MB-231) and glioblastoma (T98G) cell lines. Cellular internalisation and subcellular distribution were assessed by uptake studies and fractionation. Cytotoxicity was evaluated using MTS assays, while therapeutic efficacy in three-dimensional models was investigated in tumour spheroids. Flow cytometry was employed to analyse apoptosis and cell-cycle distribution. DNA double-strand breaks were quantified by γ-H2AX phosphorylation. Ex vivo biodistribution studies compared intratumoural and intravenous administration routes. Results: The radio-conjugate underwent straightforward synthesis, exhibited very high radio-labelling efficiency at low mercury loading, and maintained excellent colloidal stability. Efficient cellular uptake and pronounced nuclear accumulation were observed in both cell lines. In vitro studies demonstrated strong, time- and dose-dependent cytotoxicity predominantly mediated by apoptosis, with minimal necrosis, accompanied by significant induction of DNA double-strand breaks. In three-dimensional cultures, MDA-MB-231 spheroids underwent rapid, dose-dependent disintegration, whereas T98G spheroids displayed increased resistance. Ex vivo biodistribution revealed high tumour retention following intratumoural administration, minimal systemic exposure and predominantly renal clearance. Conclusions: 197mHg/197Hg-functionalised gold nanoparticles represent a promising receptor-independent platform for localised nano-brachytherapy and warrant further preclinical evaluation in aggressive and therapy-resistant tumours.

23 December 2024 in Bio-Algorithms and Med-Systems
Verified
Journal Article
Closed access
SSSahar Nosrati Shanjani
Sahar Nosrati Shanjani
EGEmilia Górzyńska
Emilia Górzyńska
MŁMonika Łyczko
Monika Łyczko
RWRafał Walczak
Rafał Walczak
AMAgnieszka Majkowska-Pilip
Agnieszka Majkowska-Pilip
ABAleksander Bilewicz
Aleksander Bilewicz
Objectives: The HER2 receptor is often overexpressed in various cancers, particularly in breast and ovarian cancers, and this overexpression significantly contributes to the growth and spread of these tumors. Trastuzumab (Herceptin) and pertuzumab (Perjeta) are widely used humanized monoclonal antibodies (mAbs) that have shown promise in treating patients with HER2-positive breast cancer. To enhance their effectiveness, mAbs have recently been combined with chemotherapeutic agents and radionuclides. The aim of our studies was to investigate the potential therapeutic use of trastuzumab and pertuzumab labeled with the Auger electron emitter – 125I. Methods: The radioimmunoconjugates synthesized using 125I and 131I were tested in various in vitro studies on SKOV-3 cells. These studies included tests for specificity, binding affinity, internalization, cytotoxicity (MTS assay) and confocal imaging. Results: The results confirmed that radio-iodinated mAbs have high affinity and internalization properties in an HER2+ cell line. In contrast to trastuzumab, significant localization of iodinated pertuzumab on the cell membrane was observed. MTS assay and spheroid studies demonstrated minor toxic effects from both radio-conjugates resulting from the combination of the mAbs' immuno-toxic effect and the interaction of Auger electrons. However, [125I]I-pertuzumab exhibited higher cytotoxicity. Conclusions: Despite high internalization, both radio-bioconjugates showed low cytotoxicity due to the lack of radionuclide localization in the cell nucleus. However, [125I]I-pertuzumab accumulated in the cell membrane, resulting in slightly higher cytotoxicity. To improve therapeutic efficacy, modifying [125I]I-trastuzumab and [125I] I-pertuzumab to transport them to the cell nucleus, e.g., using nuclear localization signal (NLS) peptides, is crucial.